Daily Roundup

CU6.ASX 4DX.ASX CVW.ASX MGH.ASX QPM.ASX

Clarity Pharmaceuticals Strengthens Position with Clinical Wins and Manufacturing Expansion

Clarity Pharmaceuticals is firing on multiple cylinders as it progresses toward commercialization. The Australian radiopharmaceutical company reported a robust cash position of $178.3 million as of June 30, 2026, providing a solid runway for its ambitious pipeline. On the clinical front, the company's SAR-bisPSMA candidate has earned three FDA Fast Track Designations, a significant vote of confidence in its potential to address unmet needs in prostate cancer treatment. Data from both SAR-bisPSMA and SARTATE have been presented at prestigious conferences, demonstrating meaningful progress.

Behind the scenes, Clarity has been quietly building out its infrastructure. The company expanded manufacturing capabilities through partnerships with Nucleus RadioPharma and SpectronRx, bolstering its supply network ahead of potential commercialization. On the governance front, Allison Rossiter joined the Board as an Independent Non-Executive Director, while Dr. Colin Biggin transitioned from his Executive Director role to Chief Operating Officer—a move that signals the company's shift toward operational maturity.

4DMedical Accelerates Growth with U.S. Expansion and Strong Revenue Gains

4DMedical is hitting its stride with a 23% revenue jump to $7.2 million for FY26, driven by higher scan volumes and impressive margins exceeding 90%. The company's big win came through a commercial agreement with SimonMed Imaging, marking its entry into the U.S. outpatient market—a pivotal moment for the company's global ambitions.

The momentum extends across its platform. 4DMedical's SaaS products are now deployed at 540 sites globally, a 39% year-over-year increase, with the company recording a standout quarter of 105,970 scans. Its CT:VQ technology received Therapeutic Goods Administration approval in Australia, paving the way for commercial deployment down under. The company also completed the acquisition of contextflow GmbH, expanding its European footprint and adding lung cancer screening capabilities to its arsenal.

Perhaps most compelling is the clinical validation. A study published in the American Journal of Respiratory and Critical Care Medicine showed that CT:VQ-guided patient selection for lung volume reduction surgery achieved a 76% response rate, significantly outpacing the current 46% benchmark. With a strong cash balance of $278 million as of June 30, 2026, 4DMedical is well-positioned to capitalize on these opportunities.

Zurich's Acquisition of ClearView Wealth Becomes Official

ClearView Wealth Limited's acquisition by Zurich Financial Services Australia Limited is now official following Supreme Court approval. Shareholders are in line for a special dividend of $0.05 per share, payable on August 12, 2026. The scheme consideration of $0.60 per share is expected to be implemented on August 20, 2026, for shareholders registered on the scheme record date of August 13. ClearView's shares have been suspended from quotation effective at the close of trading on July 31, 2026, marking the final chapter of the company's independence.

Heidelberg's Construction Materials Acquisition Gets ACCC Green Light

Heidelberg Materials Australia's acquisition of Maas Group Holdings' construction materials business has received ACCC approval, though not without strings attached. The regulator imposed conditions requiring Heidelberg to divest three concrete plants and a quarry in Queensland and New South Wales to maintain regional competition. This marks the first Phase 1 decision with conditions under Australia's new merger control regime that commenced January 1, 2026.

For MGH, the deal delivers up to $1.703 billion in cash consideration, with $1.583 billion due at settlement and an additional $120 million linked to commercial milestones. The transaction still requires Foreign Investment Review Board approval and shareholder sign-off at the Annual General Meeting on September 24, 2026, with settlement expected in October.

QPM Energy Enters Voluntary Administration

Queensland Pacific Metals has entered voluntary administration, with Mark Holland and Anthony Connelly appointed as Administrators. Separately, FTI Consulting and KordaMentha have been appointed as Receivers and Managers for certain subsidiaries. Despite the administration process, the company has managed to resume gas production activities during the quarter, with power generation operations continuing on a business-as-usual basis. QPM's cash and equivalents balance stood at $7.9 million as of June 30, 2026. The company's shares remain suspended from trading, with updates to follow as the administration process unfolds.